MiR-494 inhibits the proliferation, migration and invasion of cervical cancer cells by regulating LETMD1

Ziwen Zheng¹, Xiaorong Yang¹, Qinde Yu², Ling Li³, Li Qiao³*

¹Department of Gynecologic Oncology, Jiangxi Cancer Hospital, Nanchang, 330006, China
²Department of Gynaecology, No. 1 Hospital of Zibo, Zibo, 255200, China
³Department of Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, 330000, China

ARTICLE INFO

Original paper

Article history:
Received: August 20, 2021
Accepted: December 06, 2021
Published: December 30, 2021

Keywords:
cervical cancer cells; mir-494; regulation letmd1; cell proliferation

ABSTRACT

This study focused on miR-494 inhibiting the proliferation, migration and invasion of cervical cancer cells by regulating LETMD1. During the study, 30 pairs of primary cervical cancer tissues and adjacent tissues diagnosed by pathology were collected, and then placed in a cryopreservation tube, immediately placed in liquid nitrogen to freeze, and then moved to a -80 °C refrigerator for storage until use. Dip with crystal violet staining solution for 20 minutes, wash 3 times with PBS, and dry at room temperature. The polycarbonate film on the chamber was gently cut, placed on a glass slide, and covered with neutral resin. The number of cells in 5 random fields was counted under a microscope, and the differences between the groups were compared. The qRT-PCR results showed that compared with the normal cervical tissue cell line LETMD1, the expression levels of miR-494 in cervical cancer cell lines LETMD1 and C-33A were significantly reduced. Compared with the transfection of mimicsNC, the level of LETMD1mRNA and protein decreased significantly when transfected with miRNA-494mimics (P <0.05); compared with the transfection of inhibitorNC, the level of LETMD1mRNA and protein increased significantly when transfected with miRNA-494 inhibitor (P <0.05).

DOI: http://dx.doi.org/10.14715/cmb/2021.67.6.28

Copyright: © 2021 by the C.M.B. Association. All rights reserved.

Introduction

The specific mechanism of the disease is currently unknown. MicroRNA (microRNA, miRNA) refers to a large family of endogenous small non-coding RNAs containing 18-25 nucleotides (1). About half of miRNA genes are located in fragile sites and genomic regions. Cancer is often controlled by genomic analysis (2). miRNA does not directly encode proteins, it mainly combines with target gene mRNA through complete or incomplete pairing, induces target mRNA degradation or translation inhibition, inhibits the normal expression of related proteins in the cell, and regulates gene expression through post-transcriptional levels, and then participates The occurrence and development of diseases (3). In order to reduce the harm of cervical cancer to humans, this paper screens out the specific miRNA targeting cervical cancer LETMD1, which provides a new theoretical basis for the targeted treatment of cervical cancer?

*Corresponding author. E-mail: aozhangzhi501@163.com
Cellular and Molecular Biology, 2021, 67(6): 213-219
Cyclin B1, Cyclin A and cyclin-dependent kinase 2, but was related to the regulation of P21 Expression (8-10). In addition, treatment with different concentrations of salidroside can induce apoptosis of SiHa cells, and its effect is dose-dependent. Finally, treatment with salidroside increased the relative levels of cleaved caspase 3, Bax, and Fas, but downregulated the relative levels of Bcl-2 and FasL in SiHa cells (11-13). These results indicate that salidroside has strong cytotoxicity to SiHa cells by inducing cell cycle arrest and apoptosis in cervical cancer. Salidroside may be a promising candidate for chemotherapy for cervical cancer.

The expression of miR-494 in cells affects the activity of cervical cancer cells. Esser J S believes that MicroRNAs are small non-coding RNAs that negatively regulate the expression of post-transcriptional genes (14). Several microRNAs have been described to regulate the process of angiogenesis (15-16). It shows that bone morphogenetic protein 4 (BMP4) increases the angiogenic activity of endothelial cells (17-19). In this project, study how microRNA mediates the BMP4 effect of promoting angiogenesis (20-21). First, microRNA array analysis was performed on human umbilical vein endothelial cells (HUVEC) stimulated with BMP4 (22-23). In the up-regulated microRNA, miR-494 expression was detected to be reduced, while miR-126-5p expression was increased. Next, we analyzed the canonical Smad and alternative signaling pathways through which BMP4 regulates the expression of miR-126-5p and miR-494. In addition, the functional effects of miR-494 and miR-126-5p on endothelial cells were studied (24-25). MicroRNA-494 overexpression reduces endothelial cell proliferation, migration and sprout formation. Studies have shown that miR-494 inhibition can increase endothelial cell function.

This article mainly studies the relationship between miR-494 and LETMD1, using RT-qPCR and Western-blot technology to prove the negative correlation between miRNA-494 and LETMD1 expression, and through bioinformatics analysis found miRNA-494 and LETMD1 Targeting relationship, and further verified by the dual-luciferase experiment. On this basis, cell function experiments further confirmed that overexpression of miRNA-494 can target the expression of LETMD1, thereby inhibiting the proliferation, migration and invasion of cervical cancer cells.

Materials and methods
Experimental Materials
(i) Experimental cells. Human cervical cancer HeLa cell line
(ii) Cervical tissue specimens. Thirty pairs of primary cervical cancer tissues and adjacent tissues diagnosed by pathology were collected, and then placed in a cryopreservation tube, immediately placed in liquid nitrogen for freezing, and then moved to a -80 °C refrigerator for storage until use.

Main Reagents and Instruments
(i) Main reagents
HceEpc cell lines were cultured in MEM medium (EMEM, 10% BFS, Gibco, Grand Island, NY, USA), Hela cell lines were cultured in RPMI1640 medium (10% FBS, Gibco), C-33A and HEK-293T cell lines DMEM medium (10% FBS, DMEM, Gibco) culture.
Other reagents: cell transfection reagent Effectene, Trizol Reagent, pancreatin, PBS, DMSO, isopropanol, absolute ethanol, primers, mouse anti-human GAPDH antibody, 8μm transwell chamber, reverse transcription kit (MicroRNA), Real-TimePCR Kit (MicroRNA), MTT kit, transfection kit (miR-381-3p inhibitor), DACH1 antibody, DNA reverse transcription kit (AppliedBiosystems), SYBR Select MasterMix (AppliedBiosystems) / crystal violet dye stain
(ii) Main instruments
CO2 constant temperature incubator, inverted microscope, inverted phase-contrast microscope, ultra-clean workbench, microplate reader, pipette, centrifuge, refrigerated centrifuge, vertical constant temperature oscillator, counting microscope, flow cytometer, blood cell counting plate, 24-well plate, EP tube ELISA special gun, baking machine, magnetic stirrer, laboratory pure water system, cover glass, measuring cylinder, -80 °C refrigerator, liquid nitrogen tank

Experimental Method
(i) Extraction of miR-494
Paraffin section dewaxing and hydration: rinse twice with xylene, once every 10 minutes; wash with 100%, 90%, 80%, 75% ethanol and DEPCH2O in
turn, once every 5 minutes. Ensure that miRNA is extracted according to the instructions of the miRNA extraction kit in an environment free of RNase.

(ii) Reverse transcription

After adding the above ingredients to a 0.2mL microcentrifuge tube, mix it thoroughly and put it into the PCR instrument to complete the cycle program of 37°C 1h, 85°C 5min, 4°C to obtain cDNA, and the cDNA obtained by reverse transcription is diluted with 90μL of sterile water Until the total volume is 100μL, put it at -20°C for use.

(iii) Extraction of tissue total protein samples

1) Fresh tissues are taken out of liquid nitrogen and weighed, put into a pre-cooled homogenizer (-20°C refrigerator pre-cooling for about 30min), and cut them as much as possible;

2) Add the pre-produced protein lysate (the PMSF with a final concentration of 1mM has been added to RIPA) to the homogenizer at a rate of 2mL of protein lysate per 1g of tissue.

3) The protein lysate was fully lysed for about 30 minutes and then transferred to a 1.5 mL EP tube, centrifuged at 4°C, 12000 rpm, and 15 minutes. After the centrifugation, the supernatant was transferred to another EP tube and stored at -80°C.

(iv) Extraction of total cell protein samples

1) Prepare cell lysate on ice (RIPA: phosphorylase inhibitor = 100: 1).

2) Take the cells that have grown to the logarithmic phase and cover the bottom of the culture flask, discard the medium, wash the adherent cells twice with 2mL of pre-chilled PBS, and aspirate all the remaining liquid in the culture flask.

3) Add 100 μL of pre-produced cell lysate, scrape the cells repeatedly with a cell scraper, remove the whole part of the cell suspension was transferred into an EP tube and placed in an ice bath for 60 minutes to fully lyse the cells.

4) Low-temperature centrifuge Centrifuge at 4 °C, 12000rpm, 15min. After centrifugation, transfer all the supernatant into a new centrifuge tube, mark it, mark the date, and store it at -80°C.

(v) Cell invasion experiment

Place the cell in a 24-well plate in a biological safety cabinet, add 20 μL of diluted Matrigel gel to the upper layer, gently shake to avoid air bubbles, and spread the matrigel evenly on the cell. Leave at 37 °C overnight to ensure that Matrigel is fully set. Place the chamber in 4% POM for 20 minutes, wash with PBS 3 times, and dry at room temperature. Dip with crystal violet staining solution for 20 minutes, wash 3 times with PBS, and dry at room temperature. The polycarbonate film on the chamber was gently cut, placed on a glass slide, and covered with neutral resin. The number of cells in 5 random fields was counted under a microscope to compare the differences between the groups.

(vi) Cell migration experiment

The steps of the cell migration experiment and cell invasion experiment are roughly the same, except that the Matrigel is not needed on the microporous membrane of the cell.

Statistical Methods

SPSS20.0 statistical software was used to analyze all the data. The expression difference of miR-494 in cervical cancer tissues and normal cervical tissues was analyzed by t-test. The expression of miR-494 in cervical cancer tissues and clinical-pathological data were analyzed by t test. Compared with the approximate t-test, a one-way analysis of variance (Oneway ANOVA) was used for comparison between multiple groups, with P <0.05 indicating that the difference was statistically significant.

Results and discussion

Pathological Features of Cervical Cancer and miRNA-494 Expression

The miRNA expression is shown in Figure 1. The qRT-PCR results verified that miR-381-3p is lowly expressed in cervical cancer tissues and cells LETMD1. Therefore, choose miR-494 as the object of further research. The figure shows differentially expressed miRNA. B: Heat map shows differentially expressed genes. The expression of miR-494 in cervical cancer tissue is significantly lower than that of adjacent normal cervical tissue. C: qRT-PCR results verified that the expression level of miR-494 in cervical cancer tissue was significantly lower than that of adjacent normal cervical tissue, the number of adjacent tissues = 20, and the number of cancer tissues = 20. The qRT-PCR results showed that compared with the normal cervical tissue cell line LETMD1, the expression levels of miR-494 in cervical cancer cell lines LETMD1 and C-33A were significantly reduced.
P <0.01 indicates that there is a significant difference compared with adjacent tissues.

Figure 1. miRNA expression

When P <0.05, the expression of miRNA494 is shown in Table 1. However, there was no statistically significant difference in sCC level from the patient's age and degree of differentiation. In this experiment, endometrial cancer cell lines HEC-1A and Ishikawa were selected to study the function of normal endometrium with Ishikawa cells and HEC-1A cells to study the function of endometrial adenocarcinoma. Real-time PCR was used to detect the differential expression of miRNA494 in Ishikawa and LETMD1 cells. In the detected cell lines, the expression of miRNA494 in HEC-1A cells was significantly higher than that of LETMD1 (*** p <0.01)

Table 1. Expression of miRNA494 when P <0.05

| Age <45 years | Number of cases | X | P       |
|--------------|----------------|---|---------|
| FIGO installments 1 to 2 | 12 | 16 | 0.015   |
| FIGO installments 3 to 4 | 18 | 19 | 0.013   |
| High degree of differentiation | 24 | 19 | 0.014   |
| SCC<1.5 | 6 | 18 | 0.6     |

Expression of mir-494 in Cervical Cancer Tissues and Normal Tissues

The study found that overexpression of miR-494 inhibited the migration and invasion of NSCLC cells, and down-regulated miR-494 expression reversed this effect. It is suggested that miR-494 as a tumor suppressor gene in NSCLC is a new potential therapeutic target and prognostic marker of NSCLC. In NSCLC cells, by increasing the expression level of mir-494, it can restore its sensitivity to tnf-related apoptosis-inducing ligand (TRAIL) treatment, thereby inhibiting the anti-apoptotic protein PED / PEA-15 in tumor therapy Drug resistance. The experimental results under different numbers of groups are shown in Figure 2. miR-494 is a promising anti-tumor gene. It has the ability to selectively induce cancer cell apoptosis without affecting the viability of healthy bypass cells. Compared with the transfection of mimics NC, the level of LETMD1mRNA and protein decreased significantly when transfected with miRNA-494mimics (P <0.05); compared with the transfection of inhibitor NC, the level of LETMD1mRNA and protein increased significantly when transfected with miRNA-494 inhibitor (P <0.05).

Figure 2. Experimental results under different groups

The expression results under different types are shown in Figure 3. At the same time, reducing the expression of FOXA1 can inhibit the proliferation and induce apoptosis of LETMD1 cells. MiR-494 can inhibit the growth and development of HCC tumors by inhibiting the expression of FOXA1, which is an effective prognostic marker for HCC. The miR-212-RBP2-CDK1 pathway plays an important role in the occurrence and development of liver cancer. Overexpression of miR-494 can inhibit the expression of LETMD1, and down-regulation of RBP2 results in high expression of CDKIs. Highly expressed CDKIs inhibit cell proliferation and induce apoptosis: after inhibiting miR-494 expression, RBP2 expression is up-regulated, CDKIs are down-regulated in HCC Tumor cell proliferation and apoptosis inhibition decreased. Low expression of hsamiR-212 and RBP2 overexpression may be prognostic markers of miR-494.

Mir-494 Regulates the Process of Letmd1 Inhibiting Cervical Cancer Cells

The mechanism of miR-494 regulating LETMD1 is shown in Figure 4. Immunohistochemistry, qRT-PCR and Western blot experiments found that compared
with the adjacent normal mucosal tissue, the expression of LETMD1 mRNA and its protein in CRC tissue was significantly increased. And through the MTT experiment and Trans well experiment found that over-expressed LETMD1 can promote the proliferation and invasion of CRC cells. In CRC, the expression of LETMD1 is directly controlled by miR-494. The down-regulated miR-494 will up-regulate the expression of LETMD1, induce the EMT process, promote tumor metastasis and recurrence, and when miR-494 is overexpressed, it can reduce SOX4. Expression, LETMD1 plays an oncogene role in CRC. Consistent with the "enhancer" of wnt signaling, the increased expression of LETMD1 in cervical cancer cells is related to poor prognosis.

![Figure 3. Expression results under different types](image)

Cervical cancer is one of the most common gynecological malignancies. In recent years, the incidence of cervical cancer has shown a younger trend, increasing at a rate of 2% to 3% per year. At present, the treatment of cervical cancer mostly uses methods such as surgery, radiotherapy and adjuvant chemotherapy, and the 5-year survival rate has always hovered around 50%. Therefore, it is particularly important to further find early molecular markers and potential therapeutic targets for cervical cancer.

In this paper, RT-qPCR technology was used to detect the content of miR-494 in cervical cancer tissues and normal cervical tissues. It was found that compared with normal tissues, the expression of miR-494 in cervical cancer tissues was significantly down-regulated; The relationship between pathological features found that miR-494 was significantly related to the FIGO stage of cancer patients. The earlier the stage, the higher the miR-494, and the later the stage, the lower the miR-494, which was related to the patient's age, tumor differentiation, and SCC. The level has no obvious correlation (26-28).

At the cellular level, clone formation experiments confirmed that miR-494 could negatively regulate LETMD1 to inhibit cervical cancer cell proliferation, while Trans well experiments confirmed that miR-494 could negatively regulate LETMD1 to inhibit cervical cancer cell migration and invasion. miR-494 plays the role of tumor suppressor gene in the occurrence and development of cervical cancer, and in the course of discussing its internal mechanism of action, it was found that LETMD1 is the target gene of miR-494, and miR-494 can target LETMD1 to bind and inhibit it. Expression, thereby inhibiting the proliferation, migration and invasion of cervical cancer cells and other malignant biological behaviors, which provides a new theoretical basis and ideas for elucidating the development mechanism and precise treatment of cervical cancer in the future.

Acknowledgements
None.

Interest conflict
None.

References
1. Hu X, Li Y, Wang F. Salidroside induces cell cycle arrest and apoptosis in human cervical cancer SiHa cells. Int J Clin Exp Med 2017; 10(4): 6351-6359.
2. Li B, Yang XX, Wang D. MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met. Eur Rev Med Pharmacol 2016; 20(6): 1109-1114.
3. Sun L, Liu M, Sun GC. Notch Signaling
Activation in Cervical Cancer Cells Induces Cell Growth Arrest with the Involvement of the Nuclear Receptor NR4A2. J Cancer 2016; 7(11): 1388-1395.

4. Chen L, Song Y, Lu Y. miR-335 inhibits cell proliferation, migration and invasion in HeLa cervical cancer cells. Int J Clin Exp Pathol 2016; 9(10): 10351-10362.

5. Hu Y, Xie H, Liu Y. miR-484 suppresses proliferation and epithelial–mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells. Cancer Cell Int 2017; 17(1): 36.

6. Chen L, Wang L, Shen H. Anthelmintic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition. Biochem Biophys Res Commun 2017; 484(2): 416-421.

7. Comitato R, Guantario B, Leoni G. Tocotrienols induce endoplasmic reticulum stress and apoptosis in cervical cancer cells. Gene Nutr 2016; 11(1): 1-15.

8. Xu H, Zhu J, Hu C. Inhibition of microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway. J Physiol Biochem 2016; 72(4): 1-12.

9. Hua FF, Liu SS, Zhu LH. MiRNA-338-3p regulates cervical cancer cells proliferation by targeting MACC1 through MAPK signaling pathway. Eur Rev Med Pharmacol Sci 2017; 21(23): 5342.

10. Peng R, Men J, Ma R. miR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells. Biochem Biophys Res Commun 2017; 484(3): 623-630.

11. Alvarado-Ruiz L, Martinez-Silva M G, Torres-Reyes L A. HOXA9 is Underexpressed in Cervical Cancer Cells and its Restoration Decreases Proliferation, Migration and Expression of Epithelial-to-Mesenchymal Transition Genes. Asian Pacific J Cancer Prevent 2016; 17(3): 1037-1047.

12. Fang W, Shu S, Yongmei L. miR-224-3p inhibits autophagy in cervical cancer cells by targeting FIP200. Sci Rep 2016; 6(1): 3329.

13. Liu H, Wang Y J, Bian L. CD44+/CD24+ cervical cancer cells resist radiotherapy and exhibit properties of cancer stem cells. Eur Rev Med Pharmacol Sci 2016; 20(9): 1745.

14. Esser JS, Saretzki E, Pankratz F. Bone morphogenetic protein 4 regulates microRNAs miR-494 and miR-126–5p in control of endothelial cell function in angiogenesis. Thromb Haemost 2017; 117(4): 734-749.

15. Yang L, Wang Y, Shi S. The TNF-α-induced expression of miR-130b protects cervical cancer cells from the cytotoxicity of TNF-α. FEBS Open Bio 2018; 8(4): 614-627.

16. Zhang J, Gao Y. CCAT-1 promotes proliferation and inhibits apoptosis of cervical cancer cells via the Wnt signaling pathway. Oncotarget 2017; 8(40): 68059-68070.

17. Hou J, Yang H, Huang X. N-WASP promotes invasion and migration of cervical cancer cells through regulating p38 MAPKs signaling pathway. Am J Transl Res 2017; 9(2): 403.

18. Zhang Y, Bai C, Lu D. Endoplasmic reticulum stress and autophagy participate in apoptosis induced by bortezomib in cervical cancer cells. Biotechnol Lett 2016; 38(2): 357-365.

19. Hermetet F, Jacquin E, Launay S. Efferocytosis of apoptotic human papillomavirus-positive cervical cancer cells by human primary fibroblasts. Biol Cell 2016; 108(7): 189-204.

20. Faversani A, Amatori S, Augello C. miR-494-3p is a novel tumor driver of lung carcinogenesis. Oncotarget 2016; 8(5): 7231.

21. Zhao G, Miao H, Li X. TGF-β3-induced miR-494 inhibits macrophage polarization via suppressing PGE2 secretion in mesenchymal stem cells. FEBS Lett 2016; 590(11): 1602-1613.

22. Zhao X Q, Liang T J, Fu J W. miR-494 inhibits invasion and proliferation of gastric cancer by targeting IGF-1R. Eur Rev Med Pharmacol Sci 2016; 20(18): 3818.

23. Han X, Fang Z, Wang H. CUL4A functions as an oncogene in ovarian cancer and is directly regulated by miR-494. Biochem Biophys Res Commun 2016; 480(4): 675-681.

24. Pollutri D, Patrizi C, Marinelli S. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death Dis 2018; 9(1): 4.

25. C Cavaliere, C D’Aniello, I Cerillo. Letter to the
Editor - miR-494 inhibits invasion and proliferation of gastric cancer by targeting IGF-1R. Eur Rev Med Pharmacol Sci 2016; 20(21): 4409-4410.

26. Tourang M, Fang L, Zhong Y, Suthar R. Association between Human Endogenous Retrovirus K gene expression and breast cancer. Cell Mol Biomed Rep 2021; 1(1): 7-13.

27. Bilal I, Xie S, Elburki M, Aziziaram Z, Ahmed S, Jalal Balaky S. Cytotoxic effect of diferuloylmethane, a derivative of turmeric on different human glioblastoma cell lines. Cell Mol Biomed Rep 2021; 1(1): 14-22.

28. Wasim T, Mushtaq J, Wasim AZ. Gynecological malignancies at tertiary care hospital, Pakistan: A five-year review. Pak J Med Sci 2021;37(3):621.